The funding round was backed by Guinness Ventures, Conduit Fund, Octopus Ventures, and Macmillan Cancer Support, exceeding the company's initial €2m target.
"Supporting businesses developing scalable, meaningful impact in healthcare is a priority for us,"
Future Planet Capital led the round as the med-tech startup prepares for international market launches.
"This funding allows AMLo to embark on the next step of our journey with the resources to potentially relieve countless people with early-stage melanoma from the anxiety and follow-up burden that should be reserved for those with higher risk disease. I am delighted to welcome several new investors, and especially to see such strong additional commitment from our previous partners. Our levelling up from an academic spin-out to commercial success is critical to ensure we have the resources to further drive innovation in medical devices across our markets."